AstraZeneca Sells U.S. Rights to Crohn's Disease Drug to Perrigo
November 23 2015 - 3:04AM
Dow Jones News
By Razak Musah Baba
LONDON--AstraZeneca PLC (AZN.LN) has agreed to sell the U.S.
rights to Crohn's disease treatment Entocort to Perrigo Company PLC
(PRGO) for $380 million.
AstraZeneca, the U.K-based pharmaceutical group which is selling
off non-core assets, said on Monday that Perrigo will also acquire
authorized generic Entocort capsules marketed by Par
Pharmaceuticals. The drug is a gastroenterology medicine for
patients with mild to moderate Crohn's disease.
"Our agreement with Perrigo completes the global divestment of
Entocort, emphasizing our strategic focus on three main therapy
areas and providing further simplification of our supply chain,"
Luke Miels, an AstraZeneca executive vice president.
AstraZeneca had previously sold the rights to the drug outside
the U.S. to Tillotts Pharma AG.
The latest transaction is expected to complete by the end of
2015.
-Write to Razak Musah Baba at razak.baba@wsj.com; Twitter:
@Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
November 23, 2015 02:49 ET (07:49 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
